- Home
- BRNS vs TPST Comparison
BRNS vs TPST Comparison
Compare BRNS & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRNS
- TPST
- Stock Information
- Founded
- BRNS 2016
- TPST 2011
- Country
- BRNS United Kingdom
- TPST United States
- Employees
- BRNS N/A
- TPST N/A
- Industry
- BRNS Biotechnology: Pharmaceutical Preparations
- TPST Biotechnology: Pharmaceutical Preparations
- Sector
- BRNS Health Care
- TPST Health Care
- Exchange
- BRNS Nasdaq
- TPST Nasdaq
- Market Cap
- BRNS 48.3M
- TPST 45.5M
- IPO Year
- BRNS 2021
- TPST N/A
- Fundamental
- Price
- BRNS $1.07
- TPST $9.58
- Analyst Decision
- BRNS Strong Buy
- TPST Hold
- Analyst Count
- BRNS 1
- TPST 3
- Target Price
- BRNS $3.00
- TPST $30.00
- AVG Volume (30 Days)
- BRNS 42.9K
- TPST 54.6K
- Earning Date
- BRNS 11-05-2025
- TPST 11-11-2025
- Dividend Yield
- BRNS N/A
- TPST N/A
- EPS Growth
- BRNS N/A
- TPST N/A
- EPS
- BRNS N/A
- TPST N/A
- Revenue
- BRNS $14,969,000.00
- TPST N/A
- Revenue This Year
- BRNS N/A
- TPST N/A
- Revenue Next Year
- BRNS N/A
- TPST N/A
- P/E Ratio
- BRNS N/A
- TPST N/A
- Revenue Growth
- BRNS 1766.46
- TPST N/A
- 52 Week Low
- BRNS $0.64
- TPST $5.35
- 52 Week High
- BRNS $2.92
- TPST $20.67
- Technical
- Relative Strength Index (RSI)
- BRNS 41.80
- TPST 47.99
- Support Level
- BRNS $1.08
- TPST $9.90
- Resistance Level
- BRNS $1.20
- TPST $11.02
- Average True Range (ATR)
- BRNS 0.10
- TPST 0.62
- MACD
- BRNS -0.01
- TPST -0.20
- Stochastic Oscillator
- BRNS 22.16
- TPST 4.78
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.